Two existing drugs inhibit SARS-CoV-2, the virus that causes Covid-19, from infecting human cells in the lab, a study has found.
According to the study, published in the journal PNAS, both drugs, vacuolin-1 and apilimod, originally developed years ago, target a large enzyme called PIKfyve kinase.
Before this study, little was known about this enzyme's role in Covid-19 infection, the researchers said.
The work, which will need to be replicated in human trials, suggests a potential new target for Covid-19 therapies, they said.
"Our findings show that targeting this kinase through a small-molecule antiviral against SARS-CoV-2 may be an effective strategy to lessen the progression or seriousness